847499-27-8

Basic information

• Product Name: CEP-18770
• Synonyms: CEP-18770;[(1R)-1-[[(2S,3R)-3-Hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid;CIP 18770;CT 47098;Delanzomib;NPH 007098;DelanzoMib (CEP-18770);Boronic acid, B-[(1R)-1-[[(2S,3R)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]aMino]butyl]aMino]-3-Methylbutyl]-
• CAS NO: 847499-27-8
• Molecular Formula: C21H28BN3O5
• Molecular Weight: 413.27512
• Product Categories: Inhibitor;Inhibitors
• Mol File: 847499-27-8.mol
• Article Data: 5

Chemical Properties

• Appearance: white powder
• Density: 1.207
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• Solubility: Acetonitrile (Slightly), Chloroform (Slightly), Methanol (Slightly)
• PKA: 9.67±0.43(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: CEP-18770(CAS DataBase Reference)
• NIST Chemistry Reference: CEP-18770(847499-27-8)
• EPA Substance Registry System: CEP-18770(847499-27-8)

Safety Data

• Hazardous Substances Data: 847499-27-8(Hazardous Substances Data)

Usage

Description

CEP-18770 is a small molecule compound that has been shown to have potential therapeutic effects in various applications.

Uses

Used in Pharmaceutical Industry:
CEP-18770 is used as a proteasome inhibitor for its ability to down-modulate NF-κB, induce apoptosis, inhibit angiogenesis, and prevent M-CSF-RANKL-induced osteoclastogenesis. It has demonstrated efficacy in inhibiting the proliferation of multiple myeloma cell lines and a panel of human hematologic and solid tumor cell lines.
Used in Autoimmune Disease Treatment:
In a mouse model of fatal lupus nephritis, CEP-18770 has been shown to reduce serum levels of circulating cytokines, prevent renal tissue damage, and increase lifespan, making it a potential candidate for the treatment of autoimmune diseases.

Upstream product

• 847494-64-8 N-[(1S,2R)-1-[[[(1R)-1-1[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-hydroxypropyl]-6-phenyl-2-pyridinecarboxamide 
• 39774-28-2 6-phenyl-pyridine-2-carboxylic acid 
• 1247729-31-2 C₁₆H₁₆N₂O₄ 
• 1247729-30-1 6-phenyl-pyridine-2-carbonyl chloride 
• 514820-48-5 1,1,1-trimethyl-N-{(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}-N-(trimethylsilyl)silanamine 

Relevant articles and documents

Proteasome inhibitor delanzomib for use in the treatment of lupus

The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject Compound A.

PROTEASOME INHIBITORS AND PROCESSES FOR THEIR PREPARATION, PURIFICATION AND USE

The invention provides boronic esters of Formula (I) wherein R1, R2, R3, and R4 are as described herein, and methods for the preparation and purification thereof.

PROTEASOME INHIBITORS AND METHODS OF USING THE SAME

The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.